Company intelligence / Profile preview

LTB4

Stockholm, Sweden

Ownership: Private
Employees: ~2
Development stage: Other

Overview

LTB4 Sweden AB was a Swedish biotechnology company focused on developing therapeutics based on the inflammatory mediator leukotriene B4 (LTB4). Founded by Nobel Laureate Bengt Samuelsson, the company aimed to harness LTB4's ability to stimulate the innate immune system to treat infections and cancer. Its lead programs included an intravenous formulation for HIV and an inhaled version for bronchiectasis. Despite reaching Phase 2 clinical trials, the company entered liquidation in 2017.

Therapeutic areas: Infectious DiseasesOncologyPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Karolinska Institutet Innovations AB

Beyond the preview

Go deeper on LTB4.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTB4.

Explore the full profile